24 de julio de 2009

Insulina glargina: punto y a parte. La EMEA se pronuncia


La EMEA se pronuncia: "Due to methodological limitations the studies were found to be inconclusive and did not allow a relationship between insulin glargine and cancer to be confirmed or excluded. In addition, the Committee noted that the results of the studies were not consistent."
Falta de consistencia de los estudios;
así que punto y a parte en todo este asunto.

No hay comentarios: